English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Unregulated cell proliferation or growth is a prominent characteristic of cancer. We have previously demonstrated that LMPs (cell membrane microparticles derived from apoptotic human CEM T lymphoma cells stimulated with actinomycin D) strongly suppress the proliferation of not only human endothelial cells but also mouse Lewis lung carcinoma cells.    Methods  LMPs were generated either from CEM T cells using different stimuli or from 3 different types of lymphocytes. The effects of LMPs on cancer cell proliferation were examined using cell lines from different species and tissues. The cell cycle kinetics was evaluated by FACS and the expression of cell cycle‐related genes was determined using quantitative RT‐PCR. The in vivo anti‐tumor effect of LMPs was investigated using xenografts and allografts.    Results  LMPs at doses far above physiological levels dramatically suppressed the proliferation of cancer cells in a non species‐specific manner. LMPs selectively target high proliferating cells and their anti‐proliferative effect is not dependent on parental cell origin or stimuli. The anti‐proliferative effect of LMPs was due to induction of cell‐cycle arrest in G0/G1, with associated increases in expression of the cyclin‐dependent kinase inhibitors p15 INK4b , p16 INK4a , and p21 Cip1 . In vivo, LMPs significantly suppressed tumor growth in animal tumor models.    Conclusion  These results highlight the potential role of LMPs in modulating the growth of high proliferating cells. Given that cell‐based therapies are considered less toxic than pharmacologic approaches and have the potential to target multiple pathways in a synergistic manner, LMPs may serve as a veritable option for cancer treatment.

Anti‐proliferative and anti‐tumour effects of lymphocyte‐derived microparticles are neither species‐ nor tumour‐type specific